Cargando…

Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China

This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Y., Xu, L., He, Y. L., Pang, Y., Lu, N., Liu, J., Shen, J., Zhu, D. M., Feng, X., Wang, Y. W., Yang, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536135/
https://www.ncbi.nlm.nih.gov/pubmed/28798931
http://dx.doi.org/10.1155/2017/4563826
_version_ 1783253968531488768
author Hu, Y.
Xu, L.
He, Y. L.
Pang, Y.
Lu, N.
Liu, J.
Shen, J.
Zhu, D. M.
Feng, X.
Wang, Y. W.
Yang, C.
author_facet Hu, Y.
Xu, L.
He, Y. L.
Pang, Y.
Lu, N.
Liu, J.
Shen, J.
Zhu, D. M.
Feng, X.
Wang, Y. W.
Yang, C.
author_sort Hu, Y.
collection PubMed
description This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were 81 isolates resistant to at least one of the SLDs among 156 MDR-TB isolates (81/156, 51.9%). The rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%). Therefore, the most predominant pattern was resistant to OFX compared with other SLDs (P < 0.001). The results of sequencing showed that 80.2% OFX-resistant MDR-TB isolates contained gyrA mutation and 88.5% KAN-resistant isolates had rrs mutations with the most frequent mutation being A1401G. These results suggest that improper use of SLDs especially OFX is a real threat to effective MDR-TB treatment not only in China but also in the whole world. Furthermore the tuberculosis control agencies should carry out SLDs susceptibility testing and rapid screening in a broader population of TB patients immediately and the SLDs should be strictly regulated by the administration in order to maintain their efficacy to treat MDR-TB.
format Online
Article
Text
id pubmed-5536135
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55361352017-08-10 Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China Hu, Y. Xu, L. He, Y. L. Pang, Y. Lu, N. Liu, J. Shen, J. Zhu, D. M. Feng, X. Wang, Y. W. Yang, C. Biomed Res Int Research Article This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were 81 isolates resistant to at least one of the SLDs among 156 MDR-TB isolates (81/156, 51.9%). The rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%). Therefore, the most predominant pattern was resistant to OFX compared with other SLDs (P < 0.001). The results of sequencing showed that 80.2% OFX-resistant MDR-TB isolates contained gyrA mutation and 88.5% KAN-resistant isolates had rrs mutations with the most frequent mutation being A1401G. These results suggest that improper use of SLDs especially OFX is a real threat to effective MDR-TB treatment not only in China but also in the whole world. Furthermore the tuberculosis control agencies should carry out SLDs susceptibility testing and rapid screening in a broader population of TB patients immediately and the SLDs should be strictly regulated by the administration in order to maintain their efficacy to treat MDR-TB. Hindawi 2017 2017-07-17 /pmc/articles/PMC5536135/ /pubmed/28798931 http://dx.doi.org/10.1155/2017/4563826 Text en Copyright © 2017 Y. Hu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hu, Y.
Xu, L.
He, Y. L.
Pang, Y.
Lu, N.
Liu, J.
Shen, J.
Zhu, D. M.
Feng, X.
Wang, Y. W.
Yang, C.
Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title_full Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title_fullStr Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title_full_unstemmed Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title_short Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
title_sort prevalence and molecular characterization of second-line drugs resistance among multidrug-resistant mycobacterium tuberculosis isolates in southwest of china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536135/
https://www.ncbi.nlm.nih.gov/pubmed/28798931
http://dx.doi.org/10.1155/2017/4563826
work_keys_str_mv AT huy prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT xul prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT heyl prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT pangy prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT lun prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT liuj prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT shenj prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT zhudm prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT fengx prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT wangyw prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina
AT yangc prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina